Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Intangibles: 2017-2025

Historic Intangibles for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $172.9 million.

  • Ultragenyx Pharmaceutical's Intangibles rose 4.85% to $172.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.9 million, marking a year-over-year increase of 4.85%. This contributed to the annual value of $178.3 million for FY2024, which is 2.61% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Intangibles of $172.9 million as of Q3 2025, which was down 1.02% from $174.7 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Intangibles high stood at $178.3 million for Q4 2024, and its period low was $130.9 million during Q3 2021.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Intangibles value was $166.2 million (recorded in 2024), while the average stood at $167.9 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Intangibles climbed by 24.76% in 2022 and then decreased by 0.69% in 2023.
  • Ultragenyx Pharmaceutical's Intangibles (Quarterly) stood at $131.3 million in 2021, then grew by 24.76% to $163.8 million in 2022, then increased by 6.11% to $173.8 million in 2023, then increased by 2.61% to $178.3 million in 2024, then grew by 4.85% to $172.9 million in 2025.
  • Its last three reported values are $172.9 million in Q3 2025, $174.7 million for Q2 2025, and $176.5 million during Q1 2025.